Thermo Fisher, Pfizer partner for genomic cancer testing

• Thermo Fisher Scientific (NYSE:TMO) and Pfizer (PFE) have entered a partnership to boost access to next-generation sequencing ("NGS")-based testing for lung and breast cancer patients in countries where availability has been limited.
• The testing is used to determine the best therapy to use for a cancer patient.
• The partnership applies to 30 countries across Latin America, Africa, the Middle East, and Asia.
• The agreement calls for Thermo Fisher (TMO) to identify local labs that will be using the company's NGS technology and ensure they have the necessary infrastructure, staff, and quality control measures to meet industry standards. Pfizer (PFE) will explore ways to provide affordable patient access for NGS testing and raise healthcare provider awareness.

More on next-generation sequencing tests

• NeoGenomics stock pops on launch of next-gen sequencing tests

• Acutis to use SOPHiA's technology to develop next-gen sequencing test

• Centogene launches whole genome sequencing test CentoGenome for rare disorders